Drug intelligence / Profile preview

cerium nitrate + silver sulfadiazine

Development stage: Phase 4
Lead developer: Alliance Pharma
Modality: Small Molecules
Administration: Topical

Overview

Cerium nitrate + silver sulfadiazine is a topical antimicrobial cream composed of 2.2% cerium nitrate and 1% silver sulfadiazine. It's primarily used for managing severe burns, particularly when immediate surgical excision and grafting must be delayed. The combination produces a hardened, protective eschar that resists bacterial colonization while allowing for postponed or staged surgical intervention. Beyond its antimicrobial properties, cerium nitrate reduces progressive tissue necrosis, decreases leukocyte activation, and mitigates systemic immune dysfunction associated with severe burns.

Brand names: Flammacerium
Other names: CN+SSDCerium nitrate-silver sulfadiazine

Targets

Neuraminidase

Beyond the preview

Go deeper on cerium nitrate + silver sulfadiazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cerium nitrate + silver sulfadiazine.

Explore the full profile